SPOTLIGHT -
FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and AML
The FDA has granted an orphan drug designation to JBI-802 for the treatment of patients with small cell lung cancer and acute myeloid leukemia.
ADXS-504 Study Increases Enrollment After Confirming Safety in Recurrent Early Prostate Cancer
ADXS-504, an investigational off-the-shelf neoantigen therapy, has been reported to be well tolerated and safe in patients with biochemically recurrent early prostate cancer.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
